Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 218695, held by Amta. Topiramate.
As of Nov 15, 2026, ANDA 218695 (Topiramate), held by Amta, was first approved by FDA on Dec 3, 2024, with 1 approved supplement and 0 published complete response letters.
Topiramate extended-release capsules are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate Extended-Release Capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 3, 2024 | Original application | Approved | None posted |
| Topiramate25MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate50MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate100MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate150MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate200MG · capsule, extended release;oral | Topiramate | Rx |
| Jul 1, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 3, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters